Effect of Varenicline on Reactivity to Smoking and Drinking Cues in Individuals With Concurrent Tobacco Dependence and Alcohol Use

Completed Not Applicable NCT00873535

Study Description

Alcohol and nicotine dependence are often co-morbid, with 85% of alcoholics also smoking. However, very little research has been conducted into the nature of this co-occurrence. Thus, the main aim of this study is to assess differences in alcohol and tobacco consumption and cue-induced craving in treatment-seeking smokers after two weeks treatment of varenicline. Hypotheses 1. Two weeks of varenicline treatment will significantly decrease cue-induced tobacco craving compared to placebo (Due to the actions of varenicline on alpha-4-beta-2 receptors and its downstream effect on dopamine release). 2. Varenicline will decrease cue-induced alcohol craving compared to placebo. 3. The impact of Varenicline on cue-induced alcohol craving will be greater in heavy drinkers compared to social drinkers.

Study Details

Registry ID:
NCT00873535
Conditions:
Tobacco Dependence, Alcohol Dependence
Phase:
Not Applicable
Target Enrollment:
48 participants
Start Date:
Age Range:
18–65 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →